Desvenlafaxine SuccinatePristiq
Recommended Mental healthRestricted
Treatment of major depressive disorder (MDD) including prevention of relapse.
1
Submissions
2008–08
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Nov 2008 Recommended Antidepressant
Access path
- TGA registered · Pristiq
TGA label narrower than the PBS population
- Nov 2008Recommended · restricted
vs venlafaxine
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated.
The submission presented a cost minimisation analysis. PSD · 2008
Cost-effectiveness accepted
Decision context
PopulationAdult outpatients with major depressive disorder.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2008 | Recommended · restricted | venlafaxine | — | Meta-analysis · HAM-D17 |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to adult outpatients; TGA label does not specify setting or age group.